Laboratory of Surgery, The First Affiliated Hospital, Sun Yat-Sen (Zhongshan) University, Guangzhou, 510080 Guangdong, People's Republic of China.
Mol Biol Rep. 2011 Jun;38(5):3029-35. doi: 10.1007/s11033-010-9969-5. Epub 2010 Feb 10.
The aim of the present study is to explore possible role of miR-221 in the pathogenesis of HCC. Matched HCC and adjacent non-cancerous samples were assayed for the expression of miR-221 and three G1/S transition inhibitors: p27(Kip1), p21(WAF1/Cip1)and TGF-β1 by in situ hybridization and immunohistochemistry respectively. p27(Kip1) is one of miR-221's proven targets. Real time qRT-PCR was used to investigate miR-221 and p27(Kip1) transcripts in different clinical stages. Western blotting was used to analyze the expression levels of p27(Kip1) protein in different clinical stages. In result, miR-221 and TGF-β1 are frequently up-regulated in HCC, while p27(Kip1) and p21(WAF1/Cip1) proteins are frequently down-regulated. Moreover, miR-221 and p27(Kip1)'s expression correlated with metastasis and miR-221's expression also correlated with tumor size. Both of p21(WAF1/Cip1)and TGF-β1's expression correlated with tumor differentiations. miR-221's upregulation and p27(Kip1)'s downregulation were significantly associated with tumor stages and metastasis. In conclusion, miR-221 is important in tumorigenesis of HCC, possibly by specifically down-regulating p27(Kip1), a cell-cycle inhibitor. These results indicate miR-221 as a new therapeutic target in HCC.
本研究旨在探讨 miR-221 在 HCC 发病机制中的可能作用。通过原位杂交和免疫组织化学分别检测 miR-221 和三个 G1/S 过渡抑制剂(p27(Kip1)、p21(WAF1/Cip1)和 TGF-β1)在匹配的 HCC 和相邻非癌组织中的表达。p27(Kip1)是 miR-221 的已知靶标之一。实时 qRT-PCR 用于研究不同临床阶段的 miR-221 和 p27(Kip1)转录本。Western blot 用于分析不同临床阶段 p27(Kip1)蛋白的表达水平。结果显示,miR-221 和 TGF-β1 在 HCC 中常上调,而 p27(Kip1)和 p21(WAF1/Cip1)蛋白常下调。此外,miR-221 的表达与转移相关,miR-221 的表达也与肿瘤大小相关。p21(WAF1/Cip1)和 TGF-β1 的表达均与肿瘤分化相关。miR-221 的上调和 p27(Kip1)的下调与肿瘤分期和转移显著相关。综上所述,miR-221 在 HCC 的发生中起重要作用,可能通过特异性地下调细胞周期抑制剂 p27(Kip1)。这些结果表明 miR-221 是 HCC 的一个新的治疗靶点。